NCT03958097View on ClinicalTrials.gov

Natural Killer(NK) Cell Combined With Programmed Death-1(PD-1) Antibody as Second Line Therapy for Advanced Driver Mutation Negative Non-small Cell Lung Cancer

PHASE2CompletedINTERVENTIONAL
Enrollment

20

Participants

Timeline

Start Date

May 17, 2019

Primary Completion Date

October 21, 2020

Study Completion Date

October 21, 2021

Conditions
Non-small Cell Lung Cancer
Interventions
COMBINATION_PRODUCT

NK cell and PD-1 antibody

Each patient enrolled the study will received both NK cell and PD-1 antibody.

Trial Locations (1)

130013

First Hospital of Jilin University, Changchun

All Listed Sponsors
lead

The First Hospital of Jilin University

OTHER

NCT03958097 - Natural Killer(NK) Cell Combined With Programmed Death-1(PD-1) Antibody as Second Line Therapy for Advanced Driver Mutation Negative Non-small Cell Lung Cancer | Biotech Hunter | Biotech Hunter